Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats
RESEARCH PAPER
Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats
J John 1,M John 1,L Wu 2,C Hsiao 1,CV Abobo 3and D Liang 1
1
Department of Pharmaceutical Sciences ,College of Pharmacy and Health Sciences ,Texas
Southern University ,Houston,TX,USA,2Department of Pharmacological and Pharmaceutical Sciences ,College of Pharmacy ,University of Houston ,Houston,TX,USA,and 3Department of Pharmacy Practice ,College of Pharmacy and Health Sciences ,Texas Southern University ,Houston,TX,USA
Correspondence
Dong Liang,Department of
Pharmaceutical Sciences,College of Pharmacy and Health Sciences,Texas Southern University,3100Cleburne Street,Houston,TX 77004,USA.E-mail:liang_dx@https://www.wendangku.net/doc/054109168.html,
----------------------------------------------------------------
Keywords
warfarin;etravirine;pharmacokinetics;
pharmacodynamics;drug–drug interaction;cardiovascular;anticoagulants;LC/MS/MS
----------------------------------------------------------------
Received
25May 2012
Revised
12October 2012
Accepted
19November 2012
BACKGROUND AND PURPOSE
Warfarin is often used with etravirine (ETV)to prevent HIV-related thromboembolic events.As both warfarin and ETV bind to plasma proteins and are metabolized by hepatic cytochrome P450s,they are likely to interact.Hence,we evaluated the effect of ETV on the pharmacokinetics and blood clotting time of racemic warfarin in rats.
EXPERIMENTAL APPROACH
Two groups of male Sprague-Dawley rats,in which the jugular vein had been cannulated,were studied.The control group (n =10)received 1mg·kg -1racemic warfarin i.v.,and the test group (n =13)1mg·kg -1of racemic warfarin followed by 25mg·kg -1ETV i.v.Serial blood samples were collected for up to 144h and the blood clotting time (calculated as
international normalized ratio [INR])measured in blood plasma at each sample point.Plasma concentrations of R-warfarin,S-warfarin,R-7-hydroxywarfarin and S-7-hydroxywarfarin were measured by a LC/MS/MS method using a chiral lux cellulose-1column.Pharmacokinetic parameters were analysed using non-compartmental methods.
KEY RESULTS
ETV signi?cantly increased,by threefold,the systemic clearance and volume of distribution of S-warfarin,but not those of R-warfarin.ETV decreased the total AUC of warfarin,but had no effect on its elimination half-life.ETV also increased the systemic clearance of both R-7-hydroxywarfarin and S-7-hydroxywarfarin but only increased the volume of distribution of R-7-hydroxywarfarin.Interestingly,the effect of warfarin on blood clotting time (INR)was signi?cantly increased in the presence of etravirine.
CONCLUSION AND IMPLICATIONS
Our data suggest that etravirine may potentiate the anticoagulant effect of warfarin and this could have clinical signi?cance.
Abbreviations
Cl,clearance;ETV,etravirine;INR,international normalized ratio;MRT,mean residence time;NNRTI,non-nucleoside reverse transcriptase inhibitors;PD,pharmacodynamics;PK,pharmacokinetics;Q,blood ?ow;t 1/2,terminal half-life;Vd,volume of distribution;VKORC1,vitamin K epoxide reductase complex 1
Introduction
Warfarin is the most commonly prescribed anticoagulant in the world (Eriksson and Wadelius,2012)and is used for the
prevention of venous thromboembolism (Liu et al .,2012),for the treatment of atrial ?brillation and deep vein thrombosis (Jones et al .,2011).Warfarin extensively (99.83%)binds to the plasma protein albumin (Yacobi and Levy,1975;
Jensen
British Journal of Pharmacology
DOI:10.1111/https://www.wendangku.net/doc/054109168.html,
British Journal of Pharmacology (2013)1681851–1858
1851
?2012The Authors
British Journal of Pharmacology ?2012The British Pharmacological Society
et al.,2012)and is metabolized by a pathway that involves cytochrome P450(CYP450)(Kaminsky and Zhang,1997). These factors indicate a potential for drug–drug interactions when it is co-administered with a wide range of drugs(Chu et al.,2011).The warfarin molecule exists as enantiomers, which have identical chemical and physical properties,but exhibit different metabolic behaviour inside the body.War-farin is given to patients as a racemic mixture consisting of equal amounts of the R-and S-enantiomers.The S-enantiomer is more potent(three to seven times)than the R-enantiomer in both humans and rats(Yacobi et al.,1974; Jensen et al.,2012).Warfarin is highly metabolized in the body by a stereo-speci?c pathway catalysed by cyto-chrome P450;R-warfarin is metabolized primarily by CYP3A4to10-hydroxywarfarin and CYP1A2to6-and 8-hydroxywarfarin,while S-warfarin is metabolized primarily by CYP2C9to S-7-hydroxywarfarin(Kaminsky and Zhang, 1997).The most abundant metabolite of warfarin in humans is S-7-hydroxywarfarin(Jones et al.,2010).The elimination half-life of warfarin is relatively long,that is10–16h in animals and40–46h in humans,which may potentially cause a signi?cant change in its anticoagulant effect when it is administered concomitantly with other drugs(Panossian et al.,2009).
The anticoagulant effect of warfarin occurs through a mechanism that involves inhibition of vitamin K epoxide reductase complex1(VKORC1)and vitamin K reductase.This prevents the formation of reduced vitamin K,which is essential for the hepatic synthesis of vitamin K-dependent coagulation factors II,VII,IX and X(Zhou and Chan,2003). Clinically,one of the major challenges in warfarin therapy has arisen from the interindividual variation in response to the drug and hence deciding the correct therapeutic dose for each patient.Warfarin anticoagulant therapy is monitored by measuring the international normalized ratio(INR),a measure of three of the four vitamin K-dependent coagulation factors(II,VII and X).Normal coagulation time is indicated by an INR of1and when the INR is2the clotting time is doubled. If the INR is too high,the risk of internal bleeding is increased. Usually,a dose of10–100mg warfarin per week is suf?cient to attain an optimal balance between adverse effect and ef?cacy. Hence,warfarin is considered to be a narrow therapeutic index drug(the therapeutic window range is an INR value of 2–3,Eriksson and Wadelius,2012),and in humans,a precise control of the dosage regimen is essential.
Etravirine(ETV)is the?rst drug in the second generation of non-nucleoside reverse transcriptase inhibitors(NNRTIs) to be marketed for the treatment of HIV/AIDS.ETV is more effective than the?rst-generation NNRTIs as it is active against NNRTI-resistant HIV-1.It has properties that make it a suitable drug to be combined with other antiretrovirals for the chronic treatment of patients with HIV,who require therapy for prolonged periods of time(Bof?to et al.,2009). ETV is available in tablet form and the therapeutic dose is 200mg p.o.twice a day.Most of the ETV(99.9%)adminis-tered binds to plasma proteins(Papendorp and Berk,2009). The enzymes involved in the metabolism of ETV are CYP3A4, CYP2C9and CYP2C19(Brown et al.,2009).Interestingly, ETV,as well as being a substrate of these CYPs,also induces CYP3A4but inhibits CYP2C9and CYP2C19(Kakuda et al., 2012).
The rat model is commonly used as an animal model for the study of the effect of drug–drug and drug–herbal interac-tions on the pharmacokinetics and pharmacodynamics of drugs like warfarin(Slattery et al.,1977;Yacobi et al.,1980; Chan et al.,2009;Chu et al.,2011).It is probable that warfa-rin and ETV will interact when administered together as both are highly bound to protein and are metabolized by similar metabolic pathways.For most antiretrovirals,it is critical that their concentrations are maintained above the suggested minimum effective concentration throughout the dosing interval.However,long term use of NNRTIs can cause HIV-related thromboembolic events(Jacobson et al.,2004;Ortiz et al.,2007;Matta et al.,2008),which require the administra-tion of anticoagulants,such as warfarin.When ETV and war-farin were co-adminstered to humans,clinically,their effects suggest that a signi?cant ETV-warfarin interaction occurs (Liedtke and Rathbun,2009;Kakuda et al.,2011).Also,an increase in INR value upon co-administration of warfarin and etravirne in humans has been reported(Nutescu et al., 2011).However,information on the pharmacokinetic inter-action between warfarin and ETV is limited.Therefore,the aim of the present study was to investigate the effect of ETV on the pharmacokinetics(PK)and pharmacodynamics(PD) of warfarin.
Methods
Chemicals and reagents
Racemic warfarin,racemic7-hydroxywarfarin,acetami-nophen(Internal Standard,IS),DMSO,HPLC-grade water and acetic acid was purchased from Sigma Aldrich,St.Louis (MO,USA).ETV as the standard powder(98%pure)was from Toronto research chemicals,Inc.,North York(ON,Canada). Acetonitrile HPLC grade was from VWR International, Atlanta(GA,USA).
Pharmacokinetic studies in the rat
The animal experiment and protocol were reviewed and approved by the Institutional Animal Care and Use Commit-tee at Texas Southern University.All experimental procedures were performed in accordance with the National Institutes of Health‘Guide for the Care and Use of Laboratory Animals, 8th Edition’(NIH Publication2011).
Animals were housed separately in metabolic cages and kept in a12h light–dark cycle for a minimum of7days before being used in the experiments.The jugular veins of male adult Sprague-Dawley rats(Harlan Inc.,Indianapolis, IN,USA)weighing250–300g were cannulated under anaes-thesia the day before the study.The rats were anaesthetized with an i.m.injection of1mL kg-1bodyweight using a cock-tail containing ketamine(50mg mL-1),xylazine(3.3mg mL-1) and acetopromazine(3.3mg mL-1)in sterile water for injec-tion.Dosing solutions of racemic warfarin and ETV were prepared in normal saline and DMSO respectively.The rats were randomly divided into two groups.The treated group (n=13)received1mg·kg-1of racemic warfarin immediately followed by ETV(25mg·kg-1)i.v.,whereas the control group (n=10),received1mg·kg-1of racemic warfarin and an equal volume of DMSO(without ETV)i.v.Blood samples
(approxi-J John et al.
1852British Journal of Pharmacology(2013)1681851–1858
mately250m L)were collected from the jugular vein cannula for up to144h.The samples were centrifuged at17,383g for 10min,the plasma samples were collected,immediately stored at-80°C and analysed by an LC/MS/MS assay.All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals(Kilkenny et al.,2010;McGrath et al.,2010).
LC/MS/MS analysis of warfarin in rat plasma Plasma concentrations of R-warfarin,S-warfarin,R-7-hydroxywarfarin and S-7-hydroxywarfarin were determined by a LC/MS/MS assay method,which was previously vali-dated(John et al.,2012).Brie?y,rat plasma sample(100m L) was extracted and deproteinized by mixing it with100m L of an internal standard(IS)solution containing500ng of acetaminophen mL-1of acetonitrile.The mixture was brie?y vortexed for30s and centrifuged at17,383g for5min.Ten-microlitres of the supernatant was injected into the HPLC column.The chromatographic separation of warfarin enan-tiomers(R/S)and7-hydroxywarfarin enantiomers(R/S)was achieved using a commercially available chiral column,Lux cellulose-1with a dimension of250￥4.6mm i.d.packed with5-m m particles(Phenomenex,Torrance,CA,USA)in conjunction with a Lux Cellulose-1guard column with a dimension of4￥3.0mm(Phenomenex).A gradient elution was used,consisting of0.1%acetic acid in water(mobile phase A)and100%acetonitrile(mobile phase B).The injec-tion volume was10m L and the total run time was11min. The LC/MS/MS analysis was done by using a3200QTRAP?(AB Sciex,Foster City,CA,USA)in the negative multiple reaction monitoring mode by monitoring the m/z transi-tions323.0/176.9for7-hydroxywarfarin,m/z307→161for racemic warfarin,m/z432.9→141.6for ETV and m/z149→107for acetaminophen(I.S).
Pharmacodynamic studies in the rat
The degree of anticoagulation was assessed by means of the INR value measured by conducting a one stage INR test on the plasma sample,using a fully automated INR meter Roche CoaguChek?XS System(ThermoFisher Scienti?c,Houston, TX,USA).The INR measurements were performed on the same plasma samples collected for pharmacokinetic analysis. Approximately8m L of rat plasma was placed directly on the CoaguCheck XS PT Test test strips(ThermoFisher Scienti?c). The INR value was displayed in less than a minute and recorded.The Roche CoaguChek XS System provides test results if the INR value is between0.8and8.0.If the results fall outside of this range,the meter displays<0.8or>8.0.The Roche CoaguChek XS System has quality control functions integrated into the meter and the test strips.Hence the meter automatically runs its own quality control test as part of every test.Roche CoaguChek XS System is sensitive to various clot-ting factors including Factors II,V,VII,and X.The assay is also speci?c with no signi?cant effect on test results in the presence of bilirubin up to0.3mg·mL-1;lipaemic samples containing up to5mg·mL-1of triglcerides;haemolysis up to10mg·mL-1;heparin concentrations up to0.8U·mL-1; low molecular weight heparins up to2IU anti-factor Xa activity·mL-1;clopidogrel up to0.2mg·mL-1;and fonda-parinux up to5mg·mL-1.
In vitro effect of ETV on serum protein
binding of warfarin enantiomers
Plasma protein binding studies were conducted using an ultra ?ltration technique(Yu et al.,2012).Brie?y,freshly collected rat blank plasma samples were spiked with20m g·mL-1of racemic warfarin with and without ETV(25m g·mL-1).The plasma samples were equilibrated at37°C for30min,and then transferred to ultra?ltration centrifugal devices contain-ing Amicon?lter membranes(MW cut off=30000)and centrifuged for10min at17,383g.Aliquots of the ultra?l-trate and the top non-?ltrated plasma portion were analysed by the LC/MS/MS method.Each test was performed in triplicate.
Data analysis
Statistical interpretations of the data were conducted using SYSTAT11(SYSTAT Inc.,Evanston,IL,USA).Sample data were expressed as means?SD.Prior to the application of any statistical test,the Levene’s Test for Equality of Variances was run on the variances of the observations in the individual groups.If the variances associated with any two mean values were statistically found to be homogeneous,then Student’s t-test or Mann–Whitney U-test were used to determine the statistical signi?cance between the control and the ETV treated groups.A P-value of less than0.05was considered as statistically signi?cant.The i.v.plasma concentration-time data were pharmacokinetically analysed separately for each rat by classical non-compartmental techniques using the microcomputer-based nonlinear regression program,Win-Nonlin 2.1(Pharsight Corporation,Mountain View,CA, USA).The noncompartmental pharmacokinetic parameters thus derived were the systemic plasma clearance(Cl),the apparent volume of distribution(Vd),the total area under the plasma drug concentration-time curve extrapolated to time in?nity(AUC)and the mean residence time(MRT).
Results
Pharmacokinetics of R-warfarin and
S-warfarin when co-administered with ETV
Figure1A shows the mean plasma concentration versus time curve of R-warfarin with and without ETV.Co-administration of ETV lowered the plasma concentration of R-warfarin.The R-enantiomer in the control group was below the detection limit after96h whereas in the treated group,it was detectable up to120h.Figure1B illustrates the mean plasma concen-tration versus time pro?le for S-warfarin.Similarly,the pres-ence of ETV signi?cantly lowered the plasma concentration of S-warfarin.S-warfarin was detectable up to144h after warfarin administration.In comparison,R-warfarin appeared to be eliminated more quickly than S-warfarin.
Table1summarizes the pharmacokinetics of R-warfarin and S-warfarin.For S-warfarin,a threefold increase was observed in the systemic Cl(4.13mL·h-1·kg-1without ETV vs.
12.99mL·h-1·kg-1with ETV)as well as the Vd(115.0mL·kg-1
without ETV vs.394.2mL·kg-1with ETV).R-warfarin also showed an increase in Cl and Vd,but these values were not statistically signi?cant.ETV decreased the mean AUC?of both S-warfarin(188.7m g·h·mL-1without ETV
vs. Warfarin and etravirine drug–drug interaction
British Journal of Pharmacology(2013)1681851–18581853
36.82m g·h·mL -1with ETV)and R-warfarin (74.3m g·h·mL -1without ETV vs.24.65m g·h·mL -1with ETV).Half-life,both R-and S-warfarin did not show any statistically signi?cant dif-ference between warfarin alone or in combination with ETV
group.For controls,S-warfarin demonstrated a higher AUC and half-life,but a lower Vd and Cl compared with its R-enantiomer.
Table 2shows the pharmacokinetic parameters of the 7-hydroxywarfarin enantiomers in rats.Co-administration of ETV resulted in a signi?cant increase in the Cl for R-7-hydroxywarfarin and S-7-hydroxywarfarin.Even though there was a signi?cant,threefold,increase in the Vd for R-7-hydroxywarfarin in the presence of ETV ,the S-7-hydroxy metabolite’s increase in Vd was not signi?cant.The half-life and AUC were decreased signi?cantly in both the enantio-meric metabolites in the presence of ETV .
Pharmacodynamics of warfarin when co-administered with ETV
Figure 2shows the comparison of the INR values between the warfarin only group and the warfarin plus ETV group.As expected,the mean INR value of the ETV-treated group was increased compared with the control group.Racemic warfarin administration with or without ETV led to a wide range of INR values,as measured by the device.The blank plasma prior to warfarin administration showed a mean INR value of 1.5?0.1.The INR values measured throughout the experi-ments were in the range 2.43–8.The INR value was maximal at 24h in both groups of rats and did not show any SD.When the INR values at each time point were compared between the control and treated groups,the INR values were signi?cantly increased at 3h (P =0.0301)and 6h (P =0.0047)in the presence of ETV compared with the control group.The INR value did not return to the baseline value even after 6days of warfarin administration (INR 4.9control vs.INR 6.5treated).
In vitro effect of ETV on plasma protein binding of warfarin enantiomers
In the presence of ETV ,the amount of warfarin observed bound to protein was signi?cantly decreased (99.34%?
0.06
B
A
Figure 1
(A)Mean ?SD plasma concentration –time pro?les of R-warfarin after i.v.administration of 1mg·kg -1racemic warfarin alone (n =10)and after co-administration of 1mg·kg -1racemic warfarin and 25mg·kg -1etravirine i.v.(n =13)in male Sprague-Dawley rats.(B)Mean ?SD plasma concentration –time pro?les of S-warfarin after i.v.administration of 1mg·kg -1racemic warfarin alone (n =10)and after co-administration of 1mg·kg -1racemic warfarin and 25mg·kg -1etravirine i.v.(n =13)in male Sprague-Dawley rats.
Table 1
Comparative mean (?SD)pharmacokinetic parameters for R-warfarin and S-warfarin in male Sprague-Dawley rats after con-comitant administration of racemic warfarin and etravirine i.v.
a
Dat shown are means ?SD.*P <0.05,**P <0.01,***P <0.001.a
The rats were concomitantly administered 1mg·kg -1racemic warfarin and 25mg·kg -1etravirine i.v.
n ,number of rats employed;AUC ?,total area under the plasma concentration versus time curve;t 1/2,terminal half-life;Vd,apparent volume of distribution;Cl,systemic plasma clearance;MRT,mean residence
time.
J John et al.
1854British Journal of Pharmacology (2013)1681851–1858
vs.92.38%?0.04(+ETV),P <0.01for R-warfarin and 99.26%?0.08vs.91.79%?0.09(+ETV),P <0.01for S-warfarin).
Discussion and conclusions
The purpose of this study was to evaluate the effect of ETV on the pharmacokinetics and blood clotting time of racemic warfarin.The warfarin dose (1mg·kg -1)was chosen based on the multiple studies reported in the literature (Yacobi et al .,1980;Levi et al .,2003),whereas ETV dose was chosen based on the studies in our lab.All the rats were chosen randomly based on their body weight.Even though we started with an equal number of animals in both the control and treated groups,some rats were not used due to abnormal blood ?ow.We found that ETV signi?cantly increased the systemic clear-ance of S-warfarin,its Vd and INR value in rats,but not the terminal half-life.The increase in S-warfarin systemic Cl in the presence of ETV most likely involves warfarin displace-ment from its protein binding sites by ETV .An in vitro plasma protein binding study conducted in pooled rat plasma further con?rmed this displacement (unpublished data).Both warfa-rin and ETV are extensively bound to the plasma protein,albumin.Hence,ETV might have competitively displaced warfarin from albumin,a major binding site for warfarin.According to Bird and Carmona (2008),drugs with an exten-sive protein binding nature displace other drugs with the same characteristics when added as a cotreatment.Because warfarin has a narrow therapeutic index,this type of interac-tion,which increases its unbound plasma concentration,has prominent clinical signi?cance.The pharmacological action of warfarin is highly dependent on the unbound warfarin concentration.Based on currently available information,it is also possible that increased Cl observed for S-warfarin is due to competition for the metabolizing enzyme between S-warfarin and ETV .S-warfarin is metabolized primarily by CYP2C9.The predominant metabolizing enzymes for ETV are CYP3A4,CYP2C9and CYP 2C19.Interestingly,ETV is a sub-strate and inhibitor of CYP2C9and CYP2C19.CYP2C9plays an important role in the hepatic metabolism of both S-warfarin and ETV ,therefore,it is possible that these two drugs compete with each other for their metabolizing enzyme and thereby ETV inhibits the metabolism of S-warfarin.This would decrease systemic Cl of S-warfarin which was not the case in our study.
Previous studies have demonstrated that these types of interactions may result in changes in binding characteristics of either drug (Sands et al .,2002).The ?ndings of warfarin–ibuprofen interaction studies in rats (Slattery et al .,1977)are consistent with the notions that a highly protein-bound acidic drug like ETV will displace warfarin from the plasma proteins.Ibuprofen is extensively bound to protein in human plasma (Melillo et al .,2004)(99%versus the 99.9%for ETV)and it has a pKa of 4.4(Yazdanian et al .,2004),which compares to 3.75for ETV (Abobo et al .,2010).The warfarin–ibuprofen interaction study con?rmed that highly protein-bound acidic drugs increase the total Cl of warfarin,as observed in the present study.Moreover,an interaction study between warfarin and phenylbutazone in rats (Yacobi et al .,1980)demonstrated an increased systemic clearance of warfarin on concomitant administration of the two drugs.
Table 2
Comparative pharmacokinetic parameters for racemic 7-hydroxywarfarin in male Sprague-Dawley rats after concomitant administration of racemic warfarin and etravirine
a
Data shown are mean ?SD.*P <0.05,**P <0.01,***P <0.001.a
The rats were concomitantly administered1mg·kg -1racemic warfarin and 25mg·kg -1etravirine i.v.
n ,number of rats employed;AUC ?,total area under the plasma concentration versus time curve;t 1/2,terminal half-life;V d ,apparent volume of distribution;Cl,systemic clearance;MRT,mean residence
time.
Figure 2
Mean international normalized ratio (INR)values –time pro?le from 0.03–144h following i.v.administration of racemic warfarin (1mg·kg -1)(control group,n =6)and after co-administration of 1mg·kg -1racemic warfarin with 25mg·kg -1etravirine i.v.Data are shown as means ?SD.*P <0.05versus control for 3h and 6
h.
Warfarin and etravirine drug –drug interaction
British Journal of Pharmacology (2013)1681851–1858
1855
Phenylbutazone has extensive,98%protein-binding charac-teristics (Sulkowska et al .,2008)similar to ETV (Papendorp and Berk,2009).
In addition,theoretical considerations indicate that an essentially linear relationship exists between the systemic plasma clearance and unbound fraction of warfarin (Yacobi et al .,1980).This can be explained by following equations (see Sands et al .,2002).
Cl Q f Cl Q f Cl =()[]+()[]{}u int u int (1)
Where,Q =blood ?ow;f u =unbound fraction;and Cl int =intrinsic clearance.
For low hepatic clearance drugs,like warfarin,where Cl int is small (extraction ratio,E =0.003),Q is much larger than [f u (Cl int )].Thus,the denominator of the clearance equa-tion becomes almost equal to Q ,that is,Q +[f u (Cl int )]~Q .In other words,
Cl f Cl ～u int ()(2)
Hence,an increase in systemic clearance could be due to an increase in unbound warfarin in blood.Patients with low warfarin Cl int (e.g.cardiac and hepatic function-impaired patients)might be at greatest risk of adverse effects from this potential interaction.Even though systemic clearance of R-warfarin was increased in our study,it was not statistically signi?cant.These may be attributed to a difference in the metabolic pathways of R-warfarin and ETV .
ETV co-administration signi?cantly increased the Vd of S-warfarin in rats.This effect might be attributed to the fact that ETV administration increased the unbound warfarin concentration in plasma due to displacement of warfarin from its protein binding sites.A similar linear relationship between unbound warfarin and apparent Vd has been reported by Yacobi and Levi (1977)and Yacobi et al .(1980),explaining the protein binding of warfarin in rats.This can be explained further by the following equation (Eqn.3)(Rowland and Tozer,1995,third edition).As the unbound fraction of warfarin increases in plasma,there is an increase in the Vd.Although the Vd of R-warfarin was increased,this was not statistically signi?cant.
V V V f f =+?P TW U UT (3)
Interestingly,the increased effect of ETV observed on the Cl and Vd of the more potent S-warfarin was also associated with a signi?cant effect on warfarin pharmacodynamics.In the present study,the pharmacodynamic results obtained in the presence of ETV are in agreement with the pharmocoki-netic results.The signi?cantly increased INR values for war-farin in the presence of ETV suggest that ETV potentiates the anticoagulant action of warfarin.These increased INR values could be due to an increased free fraction of S-warfarin in blood resulting from competitive protein binding displace-ment by ETV .It should be noted that the INR values did not return to the baseline even after 6days (144h)of warfarin administration (INR 4.9control vs.INR 6.5treated).The prolonged INR value is apparently related to the higher con-centration of unbound warfarin in plasma.Similar results were observed in previous warfarin–drug interaction cases reported in patients (Liedtke and Rathbun,2009).Further-more,Nutescu et al .(2011)reported an increase in INR value upon co-administration of warfarin and ETV in humans.It is
noteworthy to point out that the terminal half-life of both R-warfarin and S-warfarin was unaffected by the presence of ETV .
ETV was recently marketed as a treatment of HIV infec-tion (Johnson and Saravolatz,2009).A study (Kakuda et al .,2011)on the pharmacokinetic interactions between warfarin and non-antiretroviral drugs reported that the INR should be monitored when combining ETV with warfarin.Moreover,Liedtke and Rathbun (2009)reported that a potential warfarin–ETV interaction is anticipated upon their concomi-tant administration.So far,four cases of warfarin–NNRTIs interaction have been reported by Liedtke et al .Interestingly,the warfarin–ETV (NNRTI)interaction reported by Liedtke et al .is very similar to that of the present study in that ETV potentiated the anticoagulant effect of warfarin.Similar to the results of our study,the INR value was increased to 7upon concomitant administration of ETV with warfarin.However,no studies have,as yet,been performed in humans or in animal models to elucidate the interaction between warfarin and ETV .
The simultaneous enantioseparation of racemic warfarin and 7-hydroxywarfarin in rat plasma was made possible by means of a chiral column (Lux cellulose -1)with superior speci?city offered by LC/MS/MS.This enabled us to simultaneously characterize R-warfarin,S-warfarin,R-7-hydroxywarfarin and S-7-hydroxywarfarin in our rat samples.Warfarin metabolism follows a highly stereo-speci?c pathway (Zhou and Chan,2002).S-warfarin is metabolized by CYP2C9to form the primary metabolite 7-hydroxywarfarin and the minor metabolite 6-hydroxywarfarin,whereas R-warfarin is principally eliminated by CYP3A4metabolism to form 10-hydroxywarfarin (Kaminsky and Zhang,1997).Because S-warfarin is the pharmacologically active form,we studied its major metabolite,S-7-hydroxywarfarin,in the present study.
Table 2shows the effect of ETV on the pharmacokinetics of 7-hydroxywarfarin.The systemic Cl and Vd for both R-and S-7-hydroxywarfarin was increased similar to their parent enantiomers.This effect could be attributed to a linear rela-tionship between intrinsic Cl and unbound free fraction of 7-hydroxy metabolite as seen in Eqn.2and 3.The AUC,half-life and MRT were decreased for both the R-and S-warfarin metabolites,probably due to the distribution of the unbound 7-hydroxy warfarin metabolite to tissues and its elimination through different pathways.
Highly stereo-selective pharmacokinetics and pharmaco-dynamics makes warfarin susceptible to numerous drug–drug interactions.S-warfarin is metabolized by the polymorphic CYP2C9enzyme and hence is the substrate selected to inves-tigate the drug–drug interactions for CYP2C9by the US Food and Drug Administration (FDA),while R-warfarin is metabo-lized by a combination of CYP isoforms including CYP1A2and CYP 3A4.It has also been reported that the anticoagulant action of racemic warfarin is mostly due to the S-warfarin and to predict any drug–drug interaction requires only the moni-toring of S-warfarin (Klein et al .,2012).
In the present study we showed that the concomitant administration of ETV with warfarin signi?cantly increased the Vd and Cl of S-warfarin.These effects may be attributed to the displacement of warfarin from protein binding sites and a competitive inhibition of S-warfarin metabolizing
enzymes
J John et al.
1856British Journal of Pharmacology (2013)1681851–1858
by ETV.The pharmacodynamic results further con?rmed this drug–drug interaction.Further clinical studies are warranted to evaluate such drug interactions in humans. Acknowledgements
This research was supported in part by a Texas Southern University seed grant and NIMHD/NIH grant (5G12RR003045-21).
Con?ict of interest
None.
References
Abobo CV,Wu L,John J,Joseph MK,Bates TR,Liang D(2010).
LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies.J Chromatogr B Analyt Technol Biomed Life Sci30:3181–3186.
Bird J,Carmona C(2008).Probable interaction between warfarin and torsemide.Ann Pharmacother42:1893–1898.
Bof?to M,Jackson A,Lamorde M,Back D,Watson V,Taylor J et al. (2009).Pharmacokinetics and safety of etravirine administered once or twice daily after2weeks treatment with efavirenz in healthy volunteers.J Acquir Immune De?c Syndr52:222–227.
Brown KC,Paul S,Kashuba ADM(2009).Drug interactions with new and investigational antiretrovirals.Clin Pharmacokinet48:
211–214.
Chan E,Hegde A,Chen X(2009).Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats.J Pharm Pharmacol61:451–458.
Chu Y,Zhang L,Wang X,Guo J,Guo Z,Ma X(2011).The effect of Compound Danshen Dripping Pills,a Chinese herb medicine,on the pharmacokinetics and pharmacodynamics of warfarin in rats.
J Ethnopharmacol137:1457–1461.
Eriksson N,Wadelius M(2012).Prediction of warfarin dose:why, when and how?Pharmacogenomics13:429–440.
Jacobson MC,Dezube BJ,Aboula?a DM(2004).Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy:a case series.Clin Infect Dis15:
1214–1222.
Jensen BP,Chin PK,Roberts RL,Begg EJ(2012).In?uence of adult age on the total and free clearance and protein binding of(R)–and (S)–warfarin.Br J Clin Pharmacol74:797–805.
John J,Robinson K,John M,Caballero J,Ma J,Liang D et al. (2012).Simultaneous LC-MS/MS determination of racemic warfarin and etravirine in rat plasma and its application in pharmacokinetic studies.In:Prasain J(ed.).Tandem Mass Spectrometry–Applications and Principles.InTech Open Access.ISBN:
978-953-51-0141-3.InTech Open Access Publisher:Rijeka,Croatia, pp.373–390.
Johnson LB,Saravolatz LD(2009).Etravirine,a next-generation nonnucleoside reverse transcriptase inhibitor.Clin Infect Dis48: 1123–1128.
Jones DR,Kim S,Guderyon M,Yun C,Moran JH,Miller GP(2010).
Hydroxywarfarin metabolites potently inhibit CYP2C9metabolism of S-warfarin.Chem Res Toxicol23:939–945.
Jones DR,Boysen G,Miller GP(2011).Novel multi-mode ultra
performance liquid chromatography-tandem mass spectrometry
assay for pro?ling enantiomeric hydroxywarfarins and warfarin in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci
879:1056–1062.
Kakuda TN,Scholler-Gyure M,Hoetelmans RM(2011).
Pharmacokinetic interactions between etravirine and
non-antiretroviral drugs.Clin Pharmacokinet50:25–39.
Kakuda TN,Van Solingen-Ristea R,Aharchi F,De Smedt G,Witek J, Nijs S et al.(2012).Pharmacokinetics and short-term safety of
etravirine in combination with?uconazole or voriconazole in
HIV-negative volunteers.J Clin Pharmacol[Epub ahead of print].
Kaminsky L,Zhang ZY(1997).Human P450metabolism of
warfarin.Pharmacol Ther73:67–74.
Kilkenny C,Browne W,Cuthill IC,Emerson M,Altman DG(2010).
NC3Rs Reporting Guidelines Working Group.Br J Pharmacol
160:1577–1579.
Klein K,Gueorguieva I,Aarons L(2012).Population
pharmacokinetic modeling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9.J Pharmacokinet
Pharmacodyn39:147–160.
Levi G,Mager DE,Cheung WK,Jusko WJ(2003).Comparative
pharmacokinetics of coumarin anticoagulants L:physiologic
modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man.J Pharm Sci92:985–994.
Liedtke MD,Rathbun RC(2009).Warfarin-antiretroviral
interactions.Ann Pharmacother43:322–329.
Liu Y,Jeong H,Takahashi H,Drozda K,Patel SR,Shapiro NL et al.
(2012).Decreased warfarin clearance associated with the CYP2C9 R15OH(*8)polymorphism.Clin Pharmacol Ther269:1–6.
McGrath J,Drummond G,McLachlan E,Kilkenny C,Wainwright C (2010).Guidelines for reporting experiments involving animals:the ARRIVE guidelines.Br J Pharmacol160:1573–1576.
Matta F,Yaekoub AY,Stein PD(2008).Human immunode?ciency virus infection and risk of venous thromboembolism.Am J Med Sci 336:402–406.
Melillo M,Phillips GJ,Davies JG,Lloyd AW,Tennison SR,
Kozynchenko OP et al.(2004).The effect of protein binding on
ibuprofen adsorption to activated carbons.Carbon42:565–571.
Nutescu E,Chuatrisorn I,Hellenbart E(2011).Drug and dietary
interactions of warfarin and novel oral anticoagulants:an update.
J Thromb Thrombolysis31:326–343.
Ortiz G,Koch S,Romano JG,Forteza AM,Rabinstein AA(2007).
Mechanisms of ischemic stroke in HIV-infected patients.Neurology 16:1257–1261.
Panossian A,Hovhannisyan A,Abrahamyan H,Gabrielyan E,
Wikman G(2009).Pharmacokinetic and pharmacodynamic study of interaction of rhodiola rosea SHR-5extract with warfarin and
theophylline in rats.Phytother Res23:351–357.
Papendorp SG,Berk GE(2009).Preoperative use of
raltegravir-containing regimen as induction therapy:very rapid
decline of HIV-1viral load.AIDS23:739–744.
Rowland M,Tozer T(1995).Clinical Pharmacokinetics:Concepts
and Applications,3rd edn.Lippincott Williams&Wilkins:
Baltimore,MD,pp.
380–381.
Warfarin and etravirine drug–drug interaction
British Journal of Pharmacology(2013)1681851–18581857
Sands CD,Chan ES,Welty TE(2002).Revisiting the signi?cance
of warfarin protein-binding displacement interactions.Ann Pharmacother36:1642–1644.
Slattery JT,Yacobi A,Levy G(1977).Comparative pharmacokinetics of coumarin anticoagulants XXV:warfarin-ibuprofen interaction in rats.J Pharm Sci66:943–947.
Sulkowska A,Macia?z˙ek-Jurczyk M,Bojko B,Równicka J,
Zubik-Skupien′I,Temba E et al.(2008).Competitive binding of phenylbutazone and colchicine to serum albumin in multidrug therapy:a spectroscopic study.J Mol Struct881:97–106.
Yacobi A,Levi G(1977).Protein binding of warfarin enantiomers
in serum of humans and rats.J Pharmacokinet Biopharm5:
123–131.
Yacobi A,Levy G(1975).Effect of plasma protein binding on the anticoagulant action of warfarin in rats.Res Commun Chem Pathol Pharmacol12:405–408.
Yacobi A,Wingard LB Jr,Levy G(1974).Comparative pharmacokinetics of coumarin anticoagulants,X.Relationship between distribution,elimination and anticoagulant action of warfarin.J Pharm Sci63:868–872.
Yacobi A,Lai C,Levy G(1980).Comparative pharmacokinetics
of coumarin anticoagulants XLV:pharmacokinetic and pharmacodyanamic studies of acute interaction between warfarin and phenylbutazone in rats.J Pharm Sci69:14–20.
Yazdanian M,Briggs K,Jankovsky C,Hawi A(2004).The‘high solubility’de?nition of the current FDA guidance on biopharmaceutical classi?cation system may be too strict for acidic drugs.Pharm Res21:293–299.
Yu L,Hong Y,Li L,Jin Y,Zheng M,Jiang H,Zeng S(2012). Enantioselective drug-protein interaction between mexiletine and plasma protein.J Pharm Pharmacol64:792–801.
Zhou Q,Chan E(2002).Effect of5-?uorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.Eur J Pharm Sci17:73–80.
Zhou Q,Chan E(2003).Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci20:
439–449.
J John et al.
1858British Journal of Pharmacology(2013)1681851–1858